Orexigen Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 90   

Articles published

OREX 2.29 0.00 (-0.22%)
price chart
Orexigen Therapeutics Announces Commercialization and Distributorship ...
SAN DIEGO, Dec. 8, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that its wholly owned subsidiary Orexigen Therapeutics Ireland Ltd.
Orexigen Therapeutics Announces Commercialization and Distributorship ...
SAN DIEGO, March 27, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd.
Orexigen Therapeutics' (OREX) CEO Mike Narachi on Q4 2016 Results ...  Seeking Alpha
Orexigen Inks Commercialization Deal for Contrave, Stock Up  Nasdaq
Orexigen Therapeutics Announces Second Quarter 2017 Financial Results
"Our performance in the second quarter of 2017 reflects the successful implementation of our commercial strategy that we launched late last year.
Orexigen Therapeutics' (OREX) CEO Mike Narachi on Q2 2017 Results ...  Seeking Alpha
Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress  Nasdaq
Orexigen Therapeutics to Present at the 35th Annual JP Morgan Healthcare ...
SAN DIEGO, Dec. 19, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the company will present at the 35th Annual J.P. Morgan Healthcare Conference 2017 in San Francisco. The presentation is scheduled for ...
Orexigen Therapeutics Launches "Brains Behind Weight Loss," a Dynamic Patient ...
SAN DIEGO, Jan. 3, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) unveiled "Brains Behind Weight Loss," a new, national direct-to-consumer advertising campaign demonstrating to patients how the brain plays an important role in weight ...
Vivus Settlement Could Clue In Orexigen Investors
Investors thought that a new anti-obesity treatment was a "no-brainer" and piled into Vivus (VVUS), Arena Pharmaceuticals (ARNA), and Orexigen (OREX). Ultimately, each company struggled in a big way to find enough patients to drive sales to respectable ...
The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen ...
Stocks recently featured in the blog include Caladrius Biosciences, Inc. (Nasdaq: CLBS - Free Report ), Orexigen Therapeutics, Inc. (Nasdaq: OREX - Free Report ), Sangamo Therapeutics, Inc. (Nasdaq: SGMO - Free Report ) and Syndax Pharmaceuticals, ...
Orexigen Therapeutics Announces Commercialization and Distributorship ...
8, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Valeant Pharmaceuticals International, Inc. (Valeant), through a wholly owned subsidiary, will commercialize Contrave� (naltrexone HCl / bupropion HCl extended ...
Orexigen Therapeutics Announces Spanish Launch of Mysimba� (naltrexone HCl ...
25, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that Laboratorios Farmac�uticos Rovi, S.A.
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended ...
He continued, "Our commercial model continues to evolve, and we expect it to become increasingly effective and more efficient, which we believe positions Orexigen to deliver strong, sustainable growth as we advance towards profitability. It's been an ...
Orexigen Therapeutics' (OREX) CEO Mike Narachi on Q1 2017 Results ...  Seeking Alpha